SG156689A1 - Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate - Google Patents
Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediateInfo
- Publication number
- SG156689A1 SG156689A1 SG200907192-9A SG2009071929A SG156689A1 SG 156689 A1 SG156689 A1 SG 156689A1 SG 2009071929 A SG2009071929 A SG 2009071929A SG 156689 A1 SG156689 A1 SG 156689A1
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- novel process
- isoxazoline derivative
- intermediate used
- isoxazoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20050016203 | 2005-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG156689A1 true SG156689A1 (en) | 2009-11-26 |
Family
ID=36927605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200907192-9A SG156689A1 (en) | 2005-02-26 | 2006-02-21 | Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate |
Country Status (29)
Country | Link |
---|---|
US (1) | US8044080B2 (no) |
EP (1) | EP1851214B1 (no) |
JP (1) | JP4961357B2 (no) |
KR (1) | KR100774999B1 (no) |
CN (1) | CN101128459B (no) |
AP (1) | AP2374A (no) |
AR (1) | AR055314A1 (no) |
AU (1) | AU2006217293B2 (no) |
BR (1) | BRPI0607330B1 (no) |
CA (1) | CA2598347C (no) |
DK (1) | DK1851214T3 (no) |
EA (1) | EA013005B1 (no) |
ES (1) | ES2394480T3 (no) |
HK (1) | HK1111146A1 (no) |
IL (1) | IL185226A0 (no) |
MA (1) | MA29311B1 (no) |
MX (1) | MX2007010338A (no) |
MY (1) | MY149181A (no) |
NO (1) | NO341347B1 (no) |
NZ (1) | NZ560805A (no) |
PE (1) | PE20061076A1 (no) |
PL (1) | PL1851214T3 (no) |
PT (1) | PT1851214E (no) |
SG (1) | SG156689A1 (no) |
SI (1) | SI1851214T1 (no) |
TW (1) | TWI377205B (no) |
UA (1) | UA94395C2 (no) |
WO (1) | WO2006090997A1 (no) |
ZA (1) | ZA200707202B (no) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101299720B1 (ko) * | 2006-08-16 | 2013-08-28 | 주식회사 엘지생명과학 | 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법 |
KR20090099886A (ko) * | 2008-03-18 | 2009-09-23 | 주식회사 엘지생명과학 | 캐스파제 저해제의 프로드럭 |
TW201012816A (en) * | 2008-07-11 | 2010-04-01 | Gilead Sciences Inc | Method of treatment and pharmaceutical compositions |
TW201011014A (en) * | 2008-07-11 | 2010-03-16 | Gilead Sciences Inc | Method of treatment and pharmaceutical compositions |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
JP6118907B2 (ja) * | 2012-09-28 | 2017-04-19 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 植物病害を防除するための窒素含有ヘテロ環式化合物 |
JP2017095353A (ja) * | 2014-03-27 | 2017-06-01 | 日本曹達株式会社 | イソオキサゾリン−5−カルボキサミド化合物および有害生物防除剤 |
JP7113831B2 (ja) * | 2017-01-23 | 2022-08-05 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | カスパーゼ阻害薬としての二環式化合物 |
JP2022529973A (ja) * | 2019-04-19 | 2022-06-27 | エルジー・ケム・リミテッド | カスパーゼ阻害剤のプロドラッグ |
JP7442914B2 (ja) * | 2019-04-30 | 2024-03-05 | エルジー・ケム・リミテッド | カスパーゼ阻害剤のプロドラッグ |
US20220226234A1 (en) * | 2019-05-31 | 2022-07-21 | Lg Chem, Ltd. | Injectable composition containing prodrug of caspase inhibitors, and preparation method therefor |
US20220226306A1 (en) * | 2019-05-31 | 2022-07-21 | Lg Chem, Ltd. | Composition for caspase inhibitor prodrug injection |
WO2022030987A1 (ko) * | 2020-08-05 | 2022-02-10 | 주식회사 엘지화학 | 캐스파제 저해제의 골관절염 완화 또는 치료에서의 용도 |
US20230414601A1 (en) | 2020-11-30 | 2023-12-28 | Lg Chem, Ltd. | Injectable composition containing caspase inhibitor, and preparation method therefor |
KR102670554B1 (ko) * | 2022-01-04 | 2024-05-30 | 주식회사 이노보테라퓨틱스 | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 |
KR20230114203A (ko) | 2022-01-24 | 2023-08-01 | 주식회사 엘지화학 | 이소옥사졸린 유도체를 포함하는 주사용 제제 |
WO2023163470A1 (ko) * | 2022-02-23 | 2023-08-31 | 주식회사 엘지화학 | 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법 |
WO2023182877A1 (ko) | 2022-03-24 | 2023-09-28 | 주식회사 엘지화학 | 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990079267A (ko) * | 1998-04-03 | 1999-11-05 | 성재갑 | 이소옥사졸(또는 이소옥사졸린) 구조를 갖는 파네실 전이효소억제제 |
KR100373375B1 (ko) * | 1998-04-03 | 2003-06-12 | 주식회사 엘지생명과학 | 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제 |
DE60013147T2 (de) * | 1999-09-17 | 2005-08-11 | Lg Chem Investment, Ltd. | Caspase-hemmer |
WO2001021599A1 (en) | 1999-09-17 | 2001-03-29 | Lg Chemical Ltd. | Caspase inhibitor |
KR100594544B1 (ko) * | 2003-08-27 | 2006-06-30 | 주식회사 엘지생명과학 | 이소옥사졸린 구조를 갖는 캐스파제 저해제 |
US7446127B2 (en) * | 2003-08-27 | 2008-11-04 | Sk Holdings Co, Ltd. | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders |
-
2006
- 2006-02-10 KR KR1020060013107A patent/KR100774999B1/ko active IP Right Grant
- 2006-02-15 TW TW095105039A patent/TWI377205B/zh active
- 2006-02-21 BR BRPI0607330-1A patent/BRPI0607330B1/pt active IP Right Grant
- 2006-02-21 US US11/816,801 patent/US8044080B2/en active Active
- 2006-02-21 EA EA200701810A patent/EA013005B1/ru unknown
- 2006-02-21 ES ES06716026T patent/ES2394480T3/es active Active
- 2006-02-21 PL PL06716026T patent/PL1851214T3/pl unknown
- 2006-02-21 DK DK06716026.7T patent/DK1851214T3/da active
- 2006-02-21 MX MX2007010338A patent/MX2007010338A/es active IP Right Grant
- 2006-02-21 NZ NZ560805A patent/NZ560805A/en unknown
- 2006-02-21 CN CN2006800059846A patent/CN101128459B/zh active Active
- 2006-02-21 EP EP06716026A patent/EP1851214B1/en active Active
- 2006-02-21 AU AU2006217293A patent/AU2006217293B2/en active Active
- 2006-02-21 JP JP2007556969A patent/JP4961357B2/ja active Active
- 2006-02-21 WO PCT/KR2006/000576 patent/WO2006090997A1/en active Application Filing
- 2006-02-21 SG SG200907192-9A patent/SG156689A1/en unknown
- 2006-02-21 UA UAA200709610A patent/UA94395C2/ru unknown
- 2006-02-21 CA CA2598347A patent/CA2598347C/en active Active
- 2006-02-21 AP AP2007004103A patent/AP2374A/xx active
- 2006-02-21 PT PT06716026T patent/PT1851214E/pt unknown
- 2006-02-21 SI SI200631425T patent/SI1851214T1/sl unknown
- 2006-02-22 MY MYPI20060748A patent/MY149181A/en unknown
- 2006-02-24 PE PE2006000221A patent/PE20061076A1/es active IP Right Grant
- 2006-02-24 AR ARP060100679A patent/AR055314A1/es active IP Right Grant
-
2007
- 2007-08-13 IL IL185226A patent/IL185226A0/en active IP Right Grant
- 2007-08-17 MA MA30152A patent/MA29311B1/fr unknown
- 2007-08-24 ZA ZA200707202A patent/ZA200707202B/xx unknown
- 2007-09-26 NO NO20074895A patent/NO341347B1/no unknown
-
2008
- 2008-02-15 HK HK08101698.5A patent/HK1111146A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG156689A1 (en) | Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate | |
MX2007005221A (es) | Formas cristalinas de ascomicina y preparacion de ellas. | |
MY147732A (en) | Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines | |
SG152274A1 (en) | Dalbavancin compositions for treatment of bacterial infections | |
TW200624426A (en) | BACE inhibitors | |
SG136953A1 (en) | Aqueous cleaning composition and method for using same | |
SG153856A1 (en) | Chemical process | |
TW200613308A (en) | Cyclobutanetetracarboxylate compound and preparation method thereof | |
SG142306A1 (en) | Methods for neuroprotection | |
WO2006079720A8 (fr) | Nouveaux derives d1oximes heterocycliques, leur procede de preparation et leur utilisation comme agents hypoglycemiants et hypoli pemiants | |
IL200000A (en) | Process for Preparing 5- (1- Alkylthio) Alkylpyridines are Stored in Position 2 and Its Compounds | |
NO20073276L (no) | Metode for fremstilling av aminoetoksybenzylalkoholer | |
IL189286A0 (en) | Novel cysteine protease inhibitors and their therapeutic applications | |
NO20091140L (no) | Fremgangsmate for fremstilling av polyester nanokompositter | |
SG158857A1 (en) | Preparation of ketone amides | |
TW200510323A (en) | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | |
SG144920A1 (en) | Method and intermediates for the preparation of derivatives of n-(1- benzhydrylazetidin-3-yl)-n-phenylmethylsulphonamide | |
WO2007063556A3 (en) | An improved and industrial process for the preparation of alfuzosin hydrochloride and its novel polymorphs | |
TW200732342A (en) | Process for the preparation of purified crystalline CCI-779 | |
NO20053829D0 (no) | Fremgangsmate og intermediater for fremstilling av olanzapin. | |
UA99579C2 (ru) | АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С Tau, ФОСФОРИЛИРОВАННЫМ ПО СЕРИНУ 422 (pS422), ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ТАУПАТИИ | |
TW200637813A (en) | Process for the preparation of Fenoldopam mesylate | |
AU2005904228A0 (en) | Stabilisation of microbiological cultures | |
SG129321A1 (en) | Method and system for prediction of allergenicity of proteins using motif table | |
CY1113832T1 (el) | Μεθοδος για την στερεοεκλεκτικη παρασκευη (-)-halofenate και παραγωγων αυτης |